Institute for Competitiveness：2025构建未来：印度生物制造战略路线图（英文版）（206页）.pdf

1、1Building Tomorrow:A Strategic Roadmap for Indias Bio-Innovation and Manufacturing Building Tomorrow A Strategic Roadmap forIndias BiomanufacturingA Strategic Roadmap forIndias Biomanufacturing Building TomorrowAMIT KAPOORHonorary Chairman,Institute for Competitiveness and Lecturer,Stanford Universi

2、tyFrom being a net importer of pharmaceuticals,India has risen to become the worlds largest provider of generic medicines,accounting for 20%of the global supply by volume.The country is also a leading vaccine manufacturer,contributing 60%of global vaccine production.Strategic investments,supportive

3、policies,and a focus on developing a skilled workforce underpin this transformation.Today,India has the highest number of US-FDA-compliant pharmaceutical plants outside the United States,and it is home to over 3,000 pharmaceutical companies with a network exceeding 10,500 manufacturing facilities.No

4、w,it is our turn to transform the bioeconomy sector.In the 202122 period,the Indian bioeconomy contributed nearly 2.6%to Indias GDP.SMEs are crucial in driving innovation and growth within Indias biotechnology industry.As of 2023,India boasts over 8,530 biotech startups,a significant increase from 3

5、,397 in 2019.This surge is fuelled by BIRACs supportive government initiatives and growing recognition of the sectors potential among the private sector.The aim of this report was to formulate the competitiveness roadmap for biomanufacturing and bio-innovation,with a specific emphasis on positioning

6、 India as a preeminent global bio-innovation hub and catalysing its trajectory towards becoming a$100 billion bio-manufacturing hub.Drawing insights from global best practices,this report also studies Lessons for India from Global Biotechnology Clusters,underscoring the importance of integrating int